Potential Psychiatric Uses for MDMA
Clinical Pharmacology & Therapeutics – November 10, 2016
Source: OpenAlex
Summary
MDMA-assisted psychotherapy is showing initial safety and efficacy for posttraumatic stress. Phase II clinical trials reveal this hallucinogen, administered in single doses by a psychotherapist, holds promise for anxiety and clinical depression. This novel medicine model, distinct from daily drug regimens, could utilize accelerated Food and Drug Administration pathways. Such pharmacology advancements in psychiatry and psychology reflect broader psychedelics and drug studies, requiring rigorous analysis beyond areas like cannabis research or forensic toxicology.
Abstract
Phase II trials of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder (PTSD), with potential for expansion to depression and anxiety disorders. In these trials, single doses of MDMA are administered in a model of medication‐assisted psychotherapy, differing from trials involving daily drug administration without psychotherapy. This model presents an opportunity to utilize accelerated regulatory pathways, such as the US Food and Drug Administration (FDA) Breakthrough Therapy Designation, to most effectively and expeditiously test such novel approaches.